Condition (MeSH)
Churg-Strauss Syndrome
ClinicalTrials.gov lists 61 trials for Churg-Strauss Syndrome or a narrower condition beneath it. GlaxoSmithKline has the most among industry and government lead sponsors, with 6.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
61 of the 61 trials are tagged with Churg-Strauss Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did Churg-Strauss Syndrome trials start? (24)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 6
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 6 |
| 2024 | 5 |
| 2023 | 3 |
| 2022 | 3 |
| 2020 | 6 |
| 2019 | 3 |
| 2018 | 4 |
| 2017 | 1 |
| 2016 | 4 |
Showing 10 of 24 earlier years.
No forecast is made for this condition: it averages 3.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 8 trials still running at the 2026-10-09 snapshot; registered median of 27 months across 34 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Churg-Strauss Syndrome trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 3 |
| Phase 2 | 7 |
| Phase 2/3 | 1 |
| Phase 3 | 10 |
| Phase 4 | 4 |
| Not applicable | 5 |
| Observational | 30 |
How many Churg-Strauss Syndrome trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 13 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 5 |
| Completed | 29 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Churg-Strauss Syndrome trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| GlaxoSmithKline | 6 |
| AstraZeneca | 4 |
| European EGPA Study Group | 2 |
| Alpine Immune Sciences, Inc. | 1 |
Which drugs are being tested for Churg-Strauss Syndrome? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| RITUXIMAB | 4 |
| Cytoxan | 4 |
| Prednisone | 2 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Mepolizumab SC | 13 |
| Benralizumab Arm B | 4 |
| Azathioprine Pill | 2 |
| Autologous Peripheral Blood Stem Cell Transplantation | 1 |
| Cyclophosphamide, Azathioprine,prednisone,methylprednisolone | 1 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Churg-Strauss Syndrome trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Asthma | 17 | 4 |
| Eosinophilic granulomatosis with polyangiitis | 10 | 3 |
| Pneumonia | 9 | 5 |
| COVID-19 | 5 | 3 |
| Cellulitis | 5 | 3 |
Showing 5 of 10 adverse events.
Which publications cover Churg-Strauss Syndrome? (37)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. | The New England journal of medicine | 2024 | Yes |
| Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis. | Nature reviews. Rheumatology | 2023 | Yes |
| Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study. | The Lancet. Rheumatology | 2023 | Yes |
| Bronchodilator Reversibility in the GAN Severe Asthma Cohort. | Journal of investigational allergology & clinical immunology | 2023 | Yes |
| Identification of autoantigens and their potential post-translational modification in EGPA and severe eosinophilic asthma. | Frontiers in immunology | 2023 | Yes |
Showing 5 of 37 publications.
Prevalence (57)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Eosinophilic granulomatosis with polyangiitis | Annual incidence | <1 / 1 000 000 | United Kingdom | GB | Exact |
| Eosinophilic granulomatosis with polyangiitis | Annual incidence | <1 / 1 000 000 | United Kingdom | GB | Exact |
| Eosinophilic granulomatosis with polyangiitis | Annual incidence | <1 / 1 000 000 | United Kingdom | GB | Unspecified |
| Eosinophilic granulomatosis with polyangiitis | Annual incidence | 1-9 / 1 000 000 | United States | US | Unspecified |
| Eosinophilic granulomatosis with polyangiitis | Annual incidence | 1-9 / 1 000 000 | United States | US | Exact |
Showing 5 of 57 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Eosinophilic granulomatosis with polyangiitis | 183 | Exact | Orphadata Science knowledge files, Product 1 |
| Eosinophilic granulomatosis with polyangiitis | 183 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.